A Study of ARRY-334543 and Docetaxel in Patients With Advanced Cancer
Status:
Completed
Trial end date:
2010-07-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1 study during which patients with advanced/metastatic solid tumors will
receive investigational study drug ARRY-334543 and docetaxel (with prophylactic growth factor
support). Patients will receive increasing doses of study drug in combination with docetaxel
in order to achieve the highest dose of study drug possible that will not cause unacceptable
side effects. Patients will be followed to see what side effects the combination causes and
what effectiveness the combination has, if any, in treating the cancer. Approximately 30
patients from the US will be enrolled in this study.
Phase:
Phase 1
Details
Lead Sponsor:
Array BioPharma Array Biopharma, now a wholly owned subsidiary of Pfizer